Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2023 | 03-2022 | 03-2021 | 03-2020 | 03-2019 | |
| Sales | 0 | 0 | 9,713 | 9,987 | 9,539 |
| Cost of Goods | N/A | N/A | 6,163 | 6,098 | 5,989 |
| Gross Profit | N/A | N/A | 3,550 | 3,889 | 3,550 |
| Operating Expenses | 20,546 | 25,529 | 27,812 | 21,206 | 15,738 |
| Operating Income | -20,546 | -25,529 | -24,262 | -17,317 | -12,188 |
| Interest Expense | 8 | 8 | 236 | 500 | 430 |
| Other Income | 1,263 | 287 | -236 | -1,532 | -64 |
| Pre-tax Income | -19,291 | -25,250 | -24,734 | -19,349 | -12,682 |
| Income Tax | N/A | 0 | 0 | -7 | 134 |
| Net Income Continuous | -19,291 | -25,250 | -24,734 | -19,342 | -12,816 |
| Net Income Discontinuous | -184 | 190 | -1,567 | N/A | N/A |
| Net Income | $-19,475 | $-25,060 | $-26,301 | $-19,342 | $-12,816 |
| EPS Basic Total Ops | -0.37 | -0.50 | -0.70 | -0.70 | -0.60 |
| EPS Basic Continuous Ops | -0.37 | -0.50 | -0.66 | -0.70 | -0.60 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | -0.04 | N/A | N/A |
| EPS Diluted Total Ops | -0.37 | -0.50 | -0.70 | -0.70 | -0.60 |
| EPS Diluted Continuous Ops | -0.37 | -0.50 | -0.66 | -0.70 | -0.60 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | -0.04 | N/A | N/A |
| EBITDA(a) | $-19,283 | $-25,143 | $-24,020 | $-18,277 | $-11,835 |